Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Cash from Financing Activities (2019 - 2026)

Enliven Therapeutics has reported Cash from Financing Activities over the past 8 years, most recently at $10.1 million for Q1 2026.

  • Quarterly results put Cash from Financing Activities at $10.1 million for Q1 2026, up 4196.15% from a year ago — trailing twelve months through Mar 2026 was $228.7 million (up 430.24% YoY), and the annual figure for FY2025 was $218.9 million, up 64.36%.
  • Cash from Financing Activities reached $10.1 million in Q1 2026 per ELVN's latest filing, up from $623000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $237.4 million in Q1 2023 and bottomed at -$2.8 million in Q2 2023.
  • Median Cash from Financing Activities over the past 5 years was $409000.0 (2022), compared with a mean of $35.0 million.
  • Peak annual rise in Cash from Financing Activities hit 57954.03% in 2023, while the deepest fall reached 56500.0% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$2.4 million in 2022, then skyrocketed by 103.79% to $90000.0 in 2023, then surged by 44313.33% to $40.0 million in 2024, then tumbled by 98.44% to $623000.0 in 2025, then skyrocketed by 1513.64% to $10.1 million in 2026.
  • Business Quant data shows Cash from Financing Activities for ELVN at $10.1 million in Q1 2026, $623000.0 in Q4 2025, and -$368000.0 in Q3 2025.